JP2008536822A - テロメラーゼ陽性細胞におけるテロメア長の調節および癌治療 - Google Patents

テロメラーゼ陽性細胞におけるテロメア長の調節および癌治療 Download PDF

Info

Publication number
JP2008536822A
JP2008536822A JP2008503271A JP2008503271A JP2008536822A JP 2008536822 A JP2008536822 A JP 2008536822A JP 2008503271 A JP2008503271 A JP 2008503271A JP 2008503271 A JP2008503271 A JP 2008503271A JP 2008536822 A JP2008536822 A JP 2008536822A
Authority
JP
Japan
Prior art keywords
cancer
cells
cell
telomerase
cancer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008503271A
Other languages
English (en)
Japanese (ja)
Inventor
ボンダレフ，イゴール，イー．
Original Assignee
アルト ソリューションズ インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルト ソリューションズ インコーポレーテッド filed Critical アルト ソリューションズ インコーポレーテッド
Publication of JP2008536822A publication Critical patent/JP2008536822A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2008503271A 2005-03-25 2006-03-27 テロメラーゼ陽性細胞におけるテロメア長の調節および癌治療 Pending JP2008536822A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66510505P 2005-03-25 2005-03-25
PCT/US2006/011027 WO2006104975A2 (en) 2005-03-25 2006-03-27 Modulation of telomere length in telomerase positive cells and cancer therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013133614A Division JP2013224953A (ja) 2005-03-25 2013-06-26 テロメラーゼ陽性細胞におけるテロメア長の調節および癌治療

Publications (1)

Publication Number Publication Date
JP2008536822A true JP2008536822A (ja) 2008-09-11

Family

ID=37053967

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008503271A Pending JP2008536822A (ja) 2005-03-25 2006-03-27 テロメラーゼ陽性細胞におけるテロメア長の調節および癌治療
JP2013133614A Pending JP2013224953A (ja) 2005-03-25 2013-06-26 テロメラーゼ陽性細胞におけるテロメア長の調節および癌治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013133614A Pending JP2013224953A (ja) 2005-03-25 2013-06-26 テロメラーゼ陽性細胞におけるテロメア長の調節および癌治療

Country Status (6)

Country Link
US (5) US7741296B2 (enExample)
EP (1) EP1868615A4 (enExample)
JP (2) JP2008536822A (enExample)
CN (2) CN101193643A (enExample)
CA (1) CA2602562C (enExample)
WO (1) WO2006104975A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008545658A (ja) * 2005-05-18 2008-12-18 アルト ソリューションズ インコーポレーテッド 癌の予防及び治療のための、癌細胞におけるテロメア長の薬理学的調節

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050113324A1 (en) * 2003-01-15 2005-05-26 Bondarev Igor E. Modulation of line-1 reverse transcriptase
WO2007106561A2 (en) * 2006-03-14 2007-09-20 Alt Solutions, Inc. Prevention and treatment of cancer and other diseases
ES2874774T3 (es) 2011-12-22 2021-11-05 Geron Corp Análogos de guanina como sustratos de telomerasa y afectores de la longitud de los telómeros
CN102660650A (zh) * 2012-05-25 2012-09-12 云南路易斯中药现代化工程技术研究中心 一种实时定量pcr测量样品中染色体端粒平均长度的绝对值的试剂盒及应用
DK2925889T3 (da) * 2012-11-30 2019-01-02 Geron Corp Diagnostiske markører til behandling af celleproliferationsforstyrrelser med telomeraseinhibitorer
US9795242B2 (en) 2013-02-14 2017-10-24 Cirkul, Inc. Additive delivery systems and containers
WO2016081925A1 (en) 2014-11-21 2016-05-26 Samsara Bottle System, Inc. Adjustable additive cartridge systems
US10888826B2 (en) 2014-11-21 2021-01-12 Cirkul, Inc. Adjustable additive cartridge systems and methods
EP3753563A1 (en) * 2019-06-20 2020-12-23 Helmholtz-Zentrum für Infektionsforschung GmbH Anti-herpesvirus guanosine analogue for the inhibition of basal autophagy
CN112168829B (zh) * 2020-09-24 2022-02-15 华南理工大学 抗病毒药物在制备治疗骨髓增生异常综合征药物中的应用及制得的骨髓增生异常综合征药物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166140A (en) * 1987-05-05 1992-11-24 City Of Hope Use of certain nucleoside analogs to attenuate cancer cell resistance to DNA damaging chemotherapy
JPH11123100A (ja) * 1992-05-13 1999-05-11 Univ Texas Syst テロメラーゼ活性調節剤のスクリーニング方法
JP2000507211A (ja) * 1996-01-26 2000-06-13 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 単純ヘルペス感染症の組合せ治療におけるヌクレオシド類似体
JP2007524668A (ja) * 2004-01-15 2007-08-30 アルト ソリューションズ インコーポレーテッド Ｌｉｎｅ−１逆転写酵素のモジュレーション

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585363A (en) * 1987-05-05 1996-12-17 City Of Hope Circumvention of human tumor drug resistance
US5654286A (en) * 1993-05-12 1997-08-05 Hostetler; Karl Y. Nucleotides for topical treatment of psoriasis, and methods for using same
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
WO1997021452A2 (en) * 1995-12-14 1997-06-19 Advanced Magnetics, Inc. Macromolecular prodrugs of nucleotide analogs
AU780815B2 (en) * 1999-06-23 2005-04-21 University Of Vermont And State Agricultural College, The Methods and products for manipulating uncoupling protein expression

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166140A (en) * 1987-05-05 1992-11-24 City Of Hope Use of certain nucleoside analogs to attenuate cancer cell resistance to DNA damaging chemotherapy
JPH11123100A (ja) * 1992-05-13 1999-05-11 Univ Texas Syst テロメラーゼ活性調節剤のスクリーニング方法
JP2000507211A (ja) * 1996-01-26 2000-06-13 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 単純ヘルペス感染症の組合せ治療におけるヌクレオシド類似体
JP2007524668A (ja) * 2004-01-15 2007-08-30 アルト ソリューションズ インコーポレーテッド Ｌｉｎｅ−１逆転写酵素のモジュレーション

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN6013007762; 医学のあゆみ １９４，　３, 2000, ｐ．１４８-１５１ *
JPN6013007765; 日本臨床 ６２，　７, 2004, ｐ．１２７７-１２８２ *
JPN6013007768; 日本臨床 ６２，　７, 2004, ｐ．１２７１-１２７６ *
JPN6013007770; 大原智子他: 日本癌学会総会記事 ６２ｎｄ, 2003, ｐ．５２６ *
JPN6013007772; 住昌彦他: 臨床血液 ４４，　８, 2003, ｐ．６７９ *
JPN7012000981; Ｎｕｃｌｅｉｃ　Ａｃｉｄｓ　Ｒｅｓｅａｒｃｈ Ｓｕｐｐｌｅｍｅｎｔ　Ｎｏ．１, 2001, ２１１-２１２ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008545658A (ja) * 2005-05-18 2008-12-18 アルト ソリューションズ インコーポレーテッド 癌の予防及び治療のための、癌細胞におけるテロメア長の薬理学的調節

Also Published As

Publication number Publication date
US8580753B2 (en) 2013-11-12
JP2013224953A (ja) 2013-10-31
US8097595B2 (en) 2012-01-17
US20120107863A1 (en) 2012-05-03
WO2006104975A2 (en) 2006-10-05
EP1868615A4 (en) 2012-06-27
US7741296B2 (en) 2010-06-22
US20140065072A1 (en) 2014-03-06
EP1868615A2 (en) 2007-12-26
WO2006104975A3 (en) 2007-12-27
CN101193643A (zh) 2008-06-04
US20100227832A1 (en) 2010-09-09
CA2602562A1 (en) 2006-10-05
CA2602562C (en) 2015-07-07
CN104997783A (zh) 2015-10-28
US20160000937A1 (en) 2016-01-07
US20090023677A1 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
US8097595B2 (en) Modulation of telomere length in telomerase positive cells and cancer therapy
US9078901B2 (en) Pharmacological modulation of telomere length in cancer cells for prevention and treatment of cancer
Röth et al. Imetelstat (GRN163L)-telomerase-based cancer therapy
US20240368607A1 (en) Synthetic rig-i-like receptor agonists
KR102294819B1 (ko) 골증식성 장애 및 골증식성 신생물의 치료를 위한 텔로메라제 저해제들의 용도
JP2016175917A (ja) 癌およびその他の疾患の予防および治療
US11884730B2 (en) Methods of sensitizing cancer to immunotherapy
Aschacher et al. The combined use of known antiviral reverse transcriptase inhibitors AZT and DDI induce anticancer effects at low concentrations
Liekens et al. The nucleotide analog cidofovir suppresses basic fibroblast growth factor (FGF2) expression and signaling and induces apoptosis in FGF2-overexpressing endothelial cells
Tomicic et al. Apoptosis induced by (E)-5-(2-bromovinyl)-2′-deoxyuridine in varicella zoster virus thymidine kinase-expressing cells is driven by activation of c-Jun/activator protein-1 and Fas ligand/caspase-8
Xiong et al. In vitro characterization of the anti-human cytomegalovirus activity of PMEA (adefovir)
Davison Imbalanced nucleotide metabolism sensitises triple negative breast cancer cell lines to standard of care chemotherapies

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120321

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120612

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120619

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120717

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120921

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130815

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130911

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140205

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140213